Medsafe warns that herbal medicines can cause side effects and may interact with prescription medicines. People with serious infections should seek medical assessment rather than relying on herbal remedies alone, because delayed treatment can be harmful.

Pneumonia is a serious infection of the lungs. Treatment depends on the cause, and bacterial pneumonia is treated with antibiotics. Herbal remedies are not presented as a substitute for antibiotic treatment of confirmed bacterial pneumonia.

The CDC describes pneumonia as an infection that can be caused by bacteria, viruses, or fungi, and notes that bacterial pneumonia is treated with antibiotics. This supports the standard-of-care distinction between infection type and appropriate treatment.

Professional organizations have issued pneumonia-related guidelines summarizing evidence-based recommendations to manage pneumonia. These guidelines include antibiotic treatment recommendations for community-acquired pneumonia and other pneumonia syndromes.

The Medsafe consumer information for a registered product called Kumerahou describes it as a traditional herbal preparation used mainly for conditions such as coughs, colds and bronchitis in rongoā Māori (traditional medicine). It does not describe Kumerahou/Pomaderris kumeraho as an antibiotic, nor as a replacement for prescribed antibacterial drugs for serious infections such as pneumonia. The document advises consumers to follow healthcare professional advice and does not recommend substituting the product for standard medical treatment in serious illness.

The NHS states that bacterial pneumonia is usually treated with antibiotics. It also distinguishes self-care from medical treatment and does not describe herbal products as a replacement for antibiotics in confirmed bacterial disease.

WHO identifies pneumonia as a major infectious disease and notes that appropriate medical care is essential, including antibiotics for bacterial pneumonia. The fact sheet does not identify kūmarahou or other herbal preparations as a replacement therapy.

This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month, children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

The New Zealand Ministry of Health states that bacterial pneumonia is usually treated with antibiotics prescribed by a doctor. It notes that prompt antibiotic treatment is important to reduce complications and that people with pneumonia should not rely on home remedies alone, but seek medical care. The page does not mention kūmarahou or Pomaderris kumeraho as a recognised treatment, and it implies that antibiotics remain the standard of care for confirmed bacterial pneumonia.

This document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia. It is a guideline for diagnosis and treatment, including antibiotic selection and duration.

For adult outpatients with CAP who reach clinical stability, we suggest less than five days of antibiotics (minimum of 3 days duration), rather than five or more days of antibiotics. This shows antibiotics are part of standard CAP treatment, with duration adjusted to clinical stability.

This review discusses herbal and non-prescription remedies for upper respiratory infection symptoms, but it does not present evidence that herbal products can replace antibiotics for confirmed bacterial pneumonia. It also notes that safety and interaction profiles vary by product and evidence base.

The trial excludes children with complicated influenza or acute respiratory viral infection when bacterial infection is present, and also excludes patients with signs of viral pneumonia. This shows that respiratory infection studies separate uncomplicated viral illness from more serious or complicated infection, rather than treating all respiratory infections as interchangeable.

This review says kūmarahou was used traditionally for respiratory lung conditions such as colds, bronchitis, and asthma, but it also states that no pre-clinical or clinical research has yet been done on this aspect of rākau rongoā use. That means the cited paper does not provide evidence that kūmarahou can treat confirmed bacterial pneumonia, much less replace antibiotics.

A pharmacological review of New Zealand native medicinal plants notes that Pomaderris kumeraho (kūmarahou) has been traditionally used by Māori primarily as an expectorant and for respiratory complaints such as coughs and bronchitis. The paper states that while some New Zealand native plants have demonstrated antimicrobial activity in vitro, there is limited or no clinical evidence that these plants, including kūmarahou, can replace modern antibiotics in treating serious bacterial infections like pneumonia. The authors call for more research and caution against assuming equivalence to standard antibiotic therapy based solely on traditional use or limited laboratory findings.

This in vitro study investigated 11 Japanese Kampo herbal formulations against Streptococcus pneumoniae and Staphylococcus aureus, common causes of pneumonia.[1] It found that some Kampo products inhibited bacterial growth with minimum inhibitory concentrations (MICs) of 6.25–50 mg/mL and suggested these products may have potential as alternative or adjunctive therapies against pneumonia-causing bacteria.[1] However, the study only reports laboratory antibacterial effects; it does not provide clinical evidence that these herbal products can replace standard antibiotics for confirmed bacterial pneumonia in humans, and it does not involve Pomaderris kumeraho or kūmarahou.

In inpatient and outpatient settings, five-day antibiotic courses are recommended, after which the patient should be verified as clinically stable with normal vital signs, normal mentation, and no difficulties with eating. Amoxicillin and doxycycline are preferred in low-risk patients.

Empirical antibiotic therapy is the cornerstone of treatment. When available, treatment of CAP should be guided by local resistance patterns. Patients should be treated for a minimum of 5 days and should be clinically stable with resolving symptoms before treatment is discontinued.

Outpatient Empiric CAP Treatment: Patients should be treated for a minimum of 5 days. Most patients are treated for 5-7 days. Doxycycline or amoxicillin are listed as preferred empiric options for previously healthy outpatients.

The article describes kumerahou as traditionally used for coughs, colds, bronchitis, and other respiratory conditions, and says it may have expectorant, anti-inflammatory, and antimicrobial effects. It also states that there is no published research on its antiviral properties and that its use is discussed as an adjunct in respiratory care, not as a proven substitute for antibiotics in bacterial pneumonia.

The document lists kumerahou as an expectorant used for upper respiratory tract infections and says no significant adverse effects have been reported to date, though excessive doses may cause vomiting in sensitive individuals. It does not provide evidence that kumerahou can treat confirmed bacterial pneumonia or replace antibiotic therapy.

This ethnobotanical record lists kūmarahou as a remedy for chest troubles such as coughs, colds, bronchitis, and pulmonary TB, and notes that its value was doubted by some. The page documents traditional use, not clinical evidence that it can replace antibiotics for confirmed bacterial pneumonia.

An indexed abstract of phytochemical work on Pomaderris kumeraho notes isolation of saponins and other constituents from the plant traditionally used in New Zealand. The summary reports that extracts showed some general antimicrobial or anti-inflammatory activity in vitro, but it does not provide minimum inhibitory concentrations against specific pneumonia pathogens, nor any clinical trials in humans. There is no suggestion in the abstract that kūmarahou has been proven effective as a stand‑alone treatment for confirmed bacterial pneumonia or as an alternative to antibiotics.

This review summarises medicinal plants studied for activity against pneumonia pathogens including Staphylococcus aureus and Streptococcus pneumoniae.[4] It reports that various plant extracts can inhibit these bacteria in vitro with inhibition zones and MIC values across a wide range, e.g. Cassia fistula aqueous extract with a 25 mm inhibition zone at 0.32 mg/mL against S. pneumoniae.[4] The authors emphasise that most evidence is laboratory-based and that clinical trials are limited; plant extracts are discussed as potential sources of new drugs or adjunctive therapies, not as established replacements for antibiotics in treating confirmed bacterial pneumonia. Pomaderris kumeraho is not listed among the plants reviewed.

Healthify NZ explains that pneumonia is usually treated with antibiotics if it is caused by bacteria, and sometimes antivirals for viral causes. It stresses that people with symptoms of pneumonia, particularly those who are unwell, elderly, or have other conditions, should see a doctor and not rely only on home or natural remedies. The page does not list kūmarahou or other rongoā plants as replacements for antibiotic therapy in confirmed bacterial pneumonia.

The available record is a toxicology summary entry rather than a clinical efficacy study. It is relevant as safety context only and does not show that kumerahou can substitute for antibiotics in bacterial pneumonia.

Confirmed bacterial pneumonia is generally treated with antibiotics because antibiotics target bacterial pathogens, while herbal products have not been established as substitutes for standard antibiotic therapy in clinical guidelines. Any claim that a specific herbal remedy can replace antibiotics would require clinical trial evidence and guideline endorsement, which is not reflected in the sources provided here.

The page says kūmarahou has been used traditionally to support respiratory health and is believed to have expectorant properties. It describes symptom-relief uses such as coughs, colds, bronchitis, and asthma, but it does not present clinical evidence that it can replace antibiotics for bacterial pneumonia.

This article says kūmarahou leaf tea was used as a tonic and was considered particularly effective for chest complaints, including coughs, colds, bronchitis, pulmonary tuberculosis, and asthma. It is historical/traditional use information rather than clinical evidence for treating confirmed bacterial pneumonia.

The page states that kūmarahou has many uses in traditional Māori medicine, although there is little scientific confirmation of its benefits. It does not provide evidence that kūmarahou can replace antibiotics for confirmed bacterial pneumonia.

This naturopathic article discusses combining botanicals with conventional treatment and says that patients with higher pneumonia risk classes should be referred for hospitalization. It does not provide clinical evidence that kūmarahou alone can replace antibiotics for confirmed bacterial pneumonia.